0.99
-0.07(-6.60%)
Currency In USD
| Previous Close | 1.06 |
| Open | 1.06 |
| Day High | 1.06 |
| Day Low | 0.98 |
| 52-Week High | 1.64 |
| 52-Week Low | 0.66 |
| Volume | 391,227 |
| Average Volume | 201,885 |
| Market Cap | 41.51M |
| PE | -2.47 |
| EPS | -0.4 |
| Moving Average 50 Days | 0.82 |
| Moving Average 200 Days | 0.95 |
| Change | -0.07 |
If you invested $1000 in SCYNEXIS, Inc. (SCYX) 10 years ago, it would be worth $13.67 as of September 18, 2025 at a share price of $0.99. Whereas If you bought $1000 worth of SCYNEXIS, Inc. (SCYX) shares 5 years ago, it would be worth $185.39 as of September 18, 2025 at a share price of $0.99.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
SCYNEXIS Announces Multiple Presentations Highlighting Data from its Second-Generation Fungerp, SCY-247, at the 12th Congress on Trends in Medical Mycology (TIMM-12)
GlobeNewswire Inc.
Sep 04, 2025 12:30 PM GMT
Oral presentation will feature data demonstrating SCY-247 in vitro activity against C. auris strains, including isolates with mutations commonly associated with echinocandin-resistanceAdditional poster presentations highlight SCY-247’s broad spectrum
SCYNEXIS to Participate in the H.C. Wainwright 27th Annual Global Conference September 8 – 10, 2025
GlobeNewswire Inc.
Aug 25, 2025 12:00 PM GMT
JERSEY CITY, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that the Scynexis
SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study
GlobeNewswire Inc.
May 28, 2025 12:30 PM GMT
First new patient dosed in Phase 3 MARIO study following the lifting of the FDA clinical holdResumption of dosing in this study triggers a $10M milestone payment from GSK plus an additional $20M milestone due in six months; as previously disclosed GS